BioNexus Gene Lab (BGLC) Long-Term Investments (2018 - 2026)

BioNexus Gene Lab's Long-Term Investments history runs 9 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed N/A year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (changed N/A YoY), while the FY2025 annual figure was $2.0 million, up 60.26% from the prior year.
• Long-Term Investments came in at $2.0 million for Q1 2026 at BioNexus Gene Lab, roughly flat from $2.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.0 million in Q1 2026 to a low of $237760.0 in Q3 2025.
• A 5-year average of $1.3 million and a median of $1.2 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments soared 68.97% in 2022 and slumped 84.35% in 2024, its largest moves.
• BioNexus Gene Lab's Long-Term Investments stood at $1.2 million in 2022, then soared by 47.7% to $1.7 million in 2023, then retreated by 25.57% to $1.3 million in 2024, then soared by 60.26% to $2.0 million in 2025, then increased by 0.05% to $2.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $2.0 million, $2.0 million, and $237760.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison